Savara Inc. walks into tonight's earnings with one of the more heavily shorted profiles in small-cap biotech, and bears have been adding to that position all month.
Short interest is running at 13.5% of the free float — meaningful pressure for a stock below $6. The position grew roughly 10% over the past month. The ORTEX short score of 71.3 places the stock in the bottom decile of the universe on this metric. What makes the setup notable is not just the level but the direction: shorts have been quietly building through April and into May, even as the stock fell 10% over the same period. Against that backdrop, borrow remains remarkably cheap at 0.56% APR, a rate that has crept up around 21% over the month but is still far from the levels that would signal a squeeze. Availability is wide, meaning there is no structural friction preventing further short-side accumulation. Options traders are leaning defensive too: the put/call ratio has climbed to 1.79, above its 20-day average of 1.40, adding another layer of downside protection ahead of the print.
The bull and bear camps are debating a question that is almost entirely binary: does Molbreevi win FDA approval in August 2026 or not? Bulls point to a clean regulatory path — positive FDA interactions, a successful BLA resubmission with Fujifilm Diosynth as drug substance manufacturer, and an expanded confirmed patient pool of roughly 5,500 aPAP patients. The recent $149.5 million equity raise and $75 million royalty funding agreement give Savara enough runway to absorb a delayed launch. Analysts who updated their views in late 2025 — HC Wainwright, Wells Fargo, Oppenheimer, Guggenheim — all maintained bullish ratings and raised targets into the $8–$11 range. The consensus mean target of $10.81 represents more than double the current $5.08 price. Bears counter that the entire investment case rests on a single asset yet to be approved, a patient population that claims data suggest is limited, and a stock that has underperformed since those target upgrades were published. All analyst data here dates from late 2025; no material rating changes have landed in the 14 days before the print.
Institutional ownership tells a story of specialist conviction. Life-science-focused funds — Bain Capital Life Sciences, Deerfield, Frazier Life Sciences, RTW Investments — dominate the top-ten holder list. Deerfield added over 5.6 million shares in the final quarter of 2025. Polar Capital and Marshall Wace each built new positions over the same period. That kind of specialist accumulation typically signals informed confidence in the clinical pathway, though the CFO's cluster of sales totalling around $588,000 in March at $5.04 per share — right near current levels — provides a more cautious counterweight.
Tonight's print is less about the quarterly financials and more about every piece of colour management offers on the August PDUFA date for Molbreevi: readiness timelines, commercial infrastructure progress, and any signal on how conversations with the FDA have evolved since the BLA resubmission.
See the live data behind this article on ORTEX.
Open SVRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
